bevacizumab,panitumumab
roche,takeda,amgen
['paradigm', 'beva', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bevacizumab', 'crcsm', 'panitumumab']
a suspicion from retrospective data has just been confirmed by the paradigm trial at #asco22: adding panitumumab to standard chemo in left-sided ras wild-type mcrc is more effective than adding bevacizumab. #crcsm
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.